EG BioMed is proud to announce that we have been awarded the prestigious “Enterprise Innovation Award” at the 22nd National Innovation Awards. Our pioneering pancreatic cancer blood detection technology has once again earned major recognition for its breakthrough potential in the field of oncology.
Pancreatic cancer is notoriously difficult to diagnose in its early stages due to the absence of clear symptoms, often leading to delayed intervention. By leveraging advanced DNA methylation and multi-biomarker analysis, EG BioMed has developed a high-precision, clinically applicable detection model designed to help medical teams identify high-risk individuals when treatment is most effective.
Technological Breakthrough in Early Detection
Our award-winning technology addresses the critical need for reliable screening tools for “the king of cancers.” By focusing on epigenetic signals, we provide a window of opportunity for clinical intervention long before traditional methods might detect a tumor.
Key Highlights of the Award-Winning Technology：
- Non-Invasive Early Risk Identification：A simple blood draw replaces invasive procedures, facilitating early-stage screening.
- Epigenetic Core Analysis：Utilizes proprietary DNA methylation markers to capture the earliest biological signals of malignancy.
- Scalable Clinical Deployment：Designed for high-volume use in diverse healthcare settings, ensuring broad accessibility.
- Proven Industrialization：Successfully transitioned from laboratory research to a commercially viable global solution.
Strategic Partnership for Global Expansion
In a significant move toward global commercialization, this technology has been officially licensed to YD Bio. Through this partnership, YD Bio will lead the international expansion and market deployment of the platform, bringing Taiwan’s biotechnology innovation to patients worldwide.
“This award is a testament to the dedication of our research team and the strength of our technological platform,” stated Dr. Jo-Kai (Linda) Lin, CSO of EG BioMed. “We extend our deepest gratitude to the review committee, our clinical partners, and the healthcare experts who have supported us throughout this journey.”
EG BioMed remains committed to advancing early cancer detection technologies. We will continue to collaborate with global industry leaders to drive the next milestones in precision medicine and improve patient outcomes everywhere.